Table 5 Coagulation disorders in 24 cases (6 men [on testosterone] and 18 women [on estrogen]) who had testosterone/hormone therapy before PE, compared to 116 cases with PE but no hormone, no cancer (62 men, 54 women), and compared to 17 cancer cases (9 men, 8 women)
Factor VIII | Factor XI | Protein C | Protein S | Free S | Antithrombin III | |
|---|---|---|---|---|---|---|
Abnormal range | > 150 % | > 150 % | < 73 % | < 63 % | < 66 % | < 80 |
Hormone Cases (n = 24, 6 men on TT, 18 women on ET) | 3/24 (13 %) | 1/23 (4 %) | 2/24 (8 %) | 5/24 (21 %) | 4/24 (17 %) | 3/24 (13 %) |
PE_no hormone, no Cancer (n = 116, 62 men, 54 women) | 27/90 (30 %)* | 8/77 (10 %) | 11/74 (15 %) | 8/80 (10 %) | ||
Cancer (n = 17, 9 men, 8 women) | 1/16 (6 %) | 1/16 (6 %) | 1/14 (7 %) |